Patents by Inventor Robert J. Gould
Robert J. Gould has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8933071Abstract: Disclosed are methods for inducing polyploidization of megakaryocyte cells and for promoting differentiation of megakaryocyte cells into platelet-producing cells. The methods may be utilized for treating blood and bone marrow diseases and disorders in a subject in need thereof and for identifying agents for treating blood and bone marrow diseases and disorders.Type: GrantFiled: November 6, 2009Date of Patent: January 13, 2015Assignees: Northwestern University, Massachusetts Institute of TechnologyInventors: John D. Crispino, Qiang Wen, Zan Huang, Andrew M. Stern, Robert J. Gould
-
Publication number: 20100120750Abstract: Disclosed are methods for inducing polyploidization of megakaryocyte cells and for promoting differentiation of megakaryocyte cells into platelet-producing cells. The methods may be utilized for treating blood and bone marrow diseases and disorders in a subject in need thereof and for identifying agents for treating blood and bone marrow diseases and disorders.Type: ApplicationFiled: November 6, 2009Publication date: May 13, 2010Applicant: Northwestern UniversityInventors: John D. Crispino, Qiang Wen, Zan Huang, Andrew M. Stern, Robert J. Gould
-
Publication number: 20090007283Abstract: Non-human transgenic animals, such as transgenic mice, are generated which incorporate the a non-native form of the bradykinin B1 receptor gene against a null phenotype for the native form of the bradykinin B1 receptor. An exemplified portion of the invention disclosed a transgenic mouse wherein a targeting construct containing a transgene encoding the human B1 bradykinin receptor gene is inserted downstream of and operatively linked to the native mice bradykinin B1 promoter. This targeting construct also contains a fluxed neomycin resistance gene. The resulting transgenic animals are “humanized” for the bradykinin B1 receptor and are effectively on a null background for native, functional B1 receptor activity. These animals may be crossed with a Cre-deleter strain to generate transgenic offspring which absent of the floxed marker gene.Type: ApplicationFiled: October 4, 2004Publication date: January 1, 2009Inventors: John W. Hess, Robert J. Gould, Douglas J. Pettibone, Thomas F. Vogt, Richard Z. Chen
-
Patent number: 6538112Abstract: The present invention is a method for diagnosing a patient at risk to thrombocytopenia induced by administration of a GP IIb/IIIa receptor antagonist, which comprises combining i) a plasma sample of the patient; ii) detectable monoclonal antibody which recognizes induced binding sites formed on the GP IIb/IIIa receptor following association of a fibrinogen receptor antagonist with the GP IIb/IIIa receptor; and iii) GP IIb/IIIa receptor:GP IIb/III receptor antagonist complex, and determining association of the detectable monoclonal antibody with the complex in the presence of the plasma.Type: GrantFiled: March 30, 2001Date of Patent: March 25, 2003Assignee: Merck & Co., Inc.Inventors: Bohumil Bednar, Daniel M. Bollag, Robert J. Gould
-
Patent number: 6403571Abstract: The instant invention involves a combination therapy and pharmaceutical compositions comprised of a therapeutically effective amount of a cholesterol reducing agent such as an HMG-CoA reductase inhibitor in combination with a platelet aggregation inhibitor which is useful for inhibiting platelet aggregation, for inhibiting the formation of thrombotic occlusions, and for treating, preventing and reducing the risk of occurrence of cardiovascular and cerebrovascular events and related vaso-occlusive disorders.Type: GrantFiled: January 18, 2001Date of Patent: June 11, 2002Assignee: Merck & Co., Inc.Inventors: Robert J. Gould, Steven A. Nichtberger, Patricia A. Rhymer, Lars Olofsson
-
Publication number: 20020009753Abstract: The present invention is a method for diagnosing a patient at risk to thrombocytopenia induced by administration of a GP IIb/IIIa receptor antagonist, which comprises combiningType: ApplicationFiled: March 30, 2001Publication date: January 24, 2002Inventors: Bohumil Bednar, Daniel M. Bollag, Robert J. Gould
-
Publication number: 20010036913Abstract: The instant invention involves a combination therapy and pharmaceutical compositions comprised of a therapeutically effective amount of a cholesterol reducing agent such as an HMG-CoA reductase inhibitor in combination with a platelet aggregation inhibitor which is useful for inhibiting platelet aggregation, for inhibiting the formation of thrombotic occlusions, and for treating, preventing and reducing the risk of occurrence of cardiovascular and cerebrovascular events and related vaso-occlusive disorders.Type: ApplicationFiled: January 18, 2001Publication date: November 1, 2001Inventors: Robert J. Gould, Steven A. Nichtberger, Patricia A. Rhymer, Lars Olofsson
-
Patent number: 6251852Abstract: The instant invention involves a combination therapy and pharmaceutical compositions comprised of a therapeutically effective amount of a cholesterol reducing agent such as an HMG-CoA reductase inhibitor in combination with a platelet aggregation inhibitor which is useful for inhibiting platelet aggregation, for inhibiting the formation of thrombotic occlusions, and for treating, preventing and reducing the risk of occurrence of cardiovascular and cerebrovascular events and related vaso-occlusive disorders.Type: GrantFiled: September 15, 1997Date of Patent: June 26, 2001Assignee: Merck & Co., Inc.Inventors: Robert J. Gould, Steven A. Nichtberger, Patricia A. Rhymer, Lars Olofsson
-
Patent number: 6235706Abstract: The present invention involves a combination therapy of administering a cholesterol reducing agent, such as a 3-hydroxy-3-methylglutaryl coenzyme a (HMG-CoA) reductase inhibitor and a platelet aggregation inhibitor for treating, preventing or reducing the risk of developing cardiovascular and cerebrovascular events and disorders in a mammal.Type: GrantFiled: May 27, 1999Date of Patent: May 22, 2001Assignee: Merck & Co., Inc.Inventors: Robert J. Gould, Steven A. Nichtberger, Patricia A. Rhymer, Lars Olofsson
-
Patent number: 6210904Abstract: The present invention is a method for diagnosing a patient at risk to thrombocytopenia induced by administration of a GP IIb/IIIa receptor antagonist, which comprises combining i) a plasma sample of the patient; ii) detectable monoclonal antibody which recognizes induced binding sites formed on the GP IIb/IIIa receptor following association of a fibrinogen receptor antagonist with the GP IIb/IIIa receptor; and iii) GP IIb/IIIa receptor:GP IIb/III receptor antagonist complex, and determining association of the detectable monoclonal antibody with the complex in the presence of the plasma.Type: GrantFiled: October 13, 1998Date of Patent: April 3, 2001Assignee: Merck & Co., Inc.Inventors: Bohumil Bednar, Daniel M. Bollag, Robert J. Gould
-
Patent number: 6136794Abstract: A method for inhibiting platelet aggregation in a mammal comprising administering to the mammal a safe and therapeutically effective amount of a GPIIb/IIIa receptor antagonist or a pharmaceutically acceptable salt thereof and a safe and therapeutically effective amount of low molecular weight heparin. A method for inhibiting platelet aggregation in a mammal comprising administering to the mammal a safe and therapeutically effective amount of (2-S-(n-butylsulfonylamino)-3[4-(piperidin-4-yl)butyloxyphenyl]-propionic acid or a pharmaceutically acceptable salt thereof and a safe and therapeutically effective amount of low molecular weight heparin.Type: GrantFiled: January 29, 1999Date of Patent: October 24, 2000Assignee: Merck & Co., Inc.Inventors: Jacquelynn J. Cook, Robert J. Gould, Frederic L. Sax
-
Patent number: 6063584Abstract: The present invention is a method for identifying a patient at risk to developing fibrinogen receptor antagonist-induced thrombocytopenia which comprises incubating patient plasma with a GPIIb/IIIa receptor:GPIIb/IIIa receptor antagonist complex to form a GPIIb/IIIa receptor:GPIIb/IIIa receptor antagonist:plasma antibody complex, incubating the GPIIb/IIIa receptor:GPIIb/IIIa receptor antagonist:plasma antibody complex with a secondary anti-human detectable antibody to form a GPIIb/IIIa receptor:GPIIb/IIIa receptor antagonist:plasma antibody:secondary anti-human detectable antibody complex, and detecting the presence of the secondary anti-human detectable antibody in the GPIIb/IIIa receptor:GPIIb/IIIa receptor antagonist:plasma antibody:secondary anti-human detectable antibody complex.Type: GrantFiled: November 21, 1997Date of Patent: May 16, 2000Assignee: Merck & Co., Inc.Inventors: Bohumil Bednar, Robert J. Gould
-
Patent number: 5900414Abstract: The compositions and methods of the invention provide a convenient means for systemically administering an integrin receptor antagonist or a pharmaceutically effective amount thereof to a patient by introducing the antagonist, in an ophthalmic formulation, to the patient's eye.Type: GrantFiled: August 26, 1997Date of Patent: May 4, 1999Assignee: Merck & Co., Inc.Inventors: Michael F. Sugrue, George D. Hartman, Robert J. Gould
-
Patent number: 5681926Abstract: Peptides having the general sequence A-B-C-D-E-F-Z wherein A is Ala, B is pFPhe, C is, for example, Arg, D is Cha, E is, for example, hArg, F is, for example, Tyr, and Z is, for example NH.sub.2. The peptides are useful for promoting wound healing and arresting bleeding in a patient.Type: GrantFiled: December 15, 1995Date of Patent: October 28, 1997Assignee: Merck & Co., Inc.Inventors: Daniel F. Veber, Ruth F. Nutt, Dong-Mei Feng, Robert J. Gould, Thomas M. Connolly
-
Patent number: 5646000Abstract: The invention is directed to a series of novel compounds, and their pharmaceutically acceptable salts, of the formula ##STR1## wherein R is C.sub.0-6 alkyl substituted with R.sup.5 or a mono or polycyclic aromatic or heteroaromatic system comprised of 5 or 6-membered aromatic or heteroaromatic rings that are either unsubstituted or substituted with one or more of R.sup.1 and R.sup.2 ; R.sup.1 and R.sup.2 are independently C.sub.1-6 alkyl, carboxyl, hydroxyl, azido, nitro, amino, C.sub.1-6 alkylamino, C.sub.1-6 dialkylamino, arylamino, aryl C.sub.1-6 alkylamino, hydroxysulfonyl or arylazo; aryl is a phenyl or naphthyl ring which is unsubstituted or substituted with one or more of R.sup.3 and R.sup.4 ; R.sup.3 and R.sup.4 are independently C.sub.1-6 alkyl, azido, nitro, amino, C.sub.1-6 dialkylamino or hydroxysulfonyl; R.sup.5 is ##STR2## provided that when R is an unsubstituted monocyclic ring, the monocyclic ring is not phenyl or pyridyl.Type: GrantFiled: September 29, 1994Date of Patent: July 8, 1997Assignee: Merck & Co., Inc.Inventors: Bohumil Bednar, Melissa Egbertson, Robert J. Gould, George D. Hartman, Jules A. Shafer
-
Patent number: 5457177Abstract: The radioligands are six amino acid peptides having iodinated tyrosine at amino acid position six, including Ala-pFPhe-hArg-Cha-hArg-Tyr(I)-NH.sub.2, which mimic the activated form of the thrombin receptor protein. Thrombin receptor radioligands of the present invention are useful for screening for thrombin receptor antagonists.Type: GrantFiled: June 16, 1993Date of Patent: October 10, 1995Assignee: Merck & Co., Inc.Inventors: Daniel F. Veber, Ruth F. Nutt, Dong-mei Feng, Robert J. Gould, Thomas M. Connolly
-
Patent number: 5217994Abstract: Compounds of the general formula ##STR1## and the pharmaceutically acceptable salts thereof whereinn is an integer of from 0 to 6;Y is CH.sub.2, O, SO.sub.2, --CONH--, --NHCO--, or ##STR2## R.sup.1 and R.sup.2 are independently hydrogen,C.sub.1-8 alkyl,heterocyclyl C.sub.0-4 alkyl,aryl C.sub.0-4 alkyl,amino C.sub.1-4 alkyl,C.sub.1-4 alkylamino C.sub.1-4 alkyl, orC.sub.3-8 cycloalkylwherein R.sup.1 and R.sup.2 may be unsubstituted or substituted with one or more groups chosen from R.sup.3, whereR.sup.3 ishydrogen,C.sub.1-6 alkyl,hydroxy C.sub.0-4 alkyl,carboxy C.sub.0-4 alkyl,C.sub.1-4 alkyloxy C.sub.0-4 alkyl,heterocyclyl C.sub.0-4 alkyl,aryl C.sub.0-4 alkyl,halogen, orCF.sub.3 ;R.sup.4 isC.sub.1-6 alkyl,heterocyclyl C.sub.0-4 alkyl, oraryl C.sub.0-4 alkyl;R.sup.5 ishydrogen,C.sub.1-6 alkyl,aryl C.sub.0-3 alkyl, orC.sub.1-6 alkylcarbonyloxymethylare used in a method of treating osteoporosis by inhibiting the bone resorption activity of osteoclasts.Type: GrantFiled: August 9, 1991Date of Patent: June 8, 1993Assignee: Merck & Co., Inc.Inventors: Melissa S. Egbertson, Robert J. Gould, George D. Hartman
-
Patent number: 5204350Abstract: Compounds of the general formula ##STR1## Y is an integer of from 0 to 6 is chosen from: O,SO.sub.2,--CONH--,--NHCO--,--CH2-- or ##STR2## R.sup.1 is substituted or unsubstituted mono- or polycyclic saturated hetero-cyclic ring system having 1, 2 or 3 heteroatoms where said heteroatoms are independently chosen from N, O and S and said substituents are chosen from the group comprising R.sup.2 ;R.sup.2 isC.sub.1-6 alkyl,aryl C.sub.0-6 alkyl,hydroxy C.sub.0-6 alkyl,C.sub.1-6 alkoxy C.sub.0-6 alkyl,carboxy C.sub.0-6 alkyloxo,halogen,CF.sub.3,C.sub.0-4 alkylamino-C.sub.0-6 alkyl orC.sub.0-4 dialkylamino-C.sub.0-6 alkyl;R.sup.3 isC.sub.1-8 alkyl or cycloalkyl,aryl C.sub.0-4 alkyl,hydroxy C.sub.0-4 alkylC.sub.1-4 alkyloxy C.sub.0-4 alkyl,carboxy C.sub.0-4 alkyl,halogen,CF.sub.3 orhydrogen;R.sup.4 ishydrogen,C.sub.1-6 alkyl,aryl C.sub.0-4 alkyl orC.sub.1-6 alkylcarbonyloxymethyl; andR.sup.5 isC.sub.1-6 alkyl,aryl C.sub.0-4 alkyl orheterocycly C.sub.Type: GrantFiled: August 9, 1991Date of Patent: April 20, 1993Assignee: Merck & Co., Inc.Inventors: Melissa S. Egbertson, George D. Hartman, Robert J. Gould
-
Patent number: 4520112Abstract: A method for measuring the level of organic calcium antagonist drug in a body fluid comprises preparing a mixture of a radioactive calcium antagonist drug, a body fluid containing a calcium antagonist drug and a calcium antagonist receptor material, measuring the radioactivity of the radioactive calcium antagonist drug bound to said calcium antagonist receptor material and deriving the concentration of the calcium antagonist drug in the body fluid from a standard curve indicating the concentration of calcium antagonist drug versus inhibition of binding of said radioactive calcium antagonist drug to said receptor sites caused by the calcium antagonist drug in said body fluid. A kit for measuring the level of an organic calcium drug comprises a receptacle containing a radioactive calcium antagonist drug, a calcium antagonist receptor material and a standard amount of a nonradioactive calcium antagonist drug.Type: GrantFiled: March 9, 1983Date of Patent: May 28, 1985Assignee: The Johns Hopkins UniversityInventors: Solomon H. Snyder, Robert J. Gould